
Opinion|Videos|January 1, 2025
Examining Elafibranor as a Treatment Option for PBC
Panelists discuss how elafibranor demonstrated significant efficacy in the ELATIVE trial, which strengthens confidence in its role as a long-term treatment option for patients with primary biliary cholangitis (PBC) who inadequately respond to ursodeoxycholic acid.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Elafibranor received accelerated approval based on findings from the
ELATIVE study. What are the key efficacy insights from this trial? - Elafibranor was also demonstrated to have long-term safety and efficacy at 3 years. How does this durability affect your clinical decision-making?
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Implementing Enfortumab Vedotin-ejfv Plus Pembrolizumab: Navigating Safety Data and the Pharmacist’s Role
2
Daratumumab Boosts Depth and Durability of Response After ASCT, Offering Clear Guidance for Pharmacist Counseling
3
Improving Outcomes in Diffuse B-Cell Lymphoma Requires Multidisciplinary Evolution
4
ACIP Votes to End Universal Hepatitis B Vaccination Recommendation for Infants
5
















































































































































































































